Multicenter Italian Cohort Study on Tuberculosis in Pediatric Age

NCT ID: NCT06289660

Last Updated: 2024-03-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-22

Study Completion Date

2033-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

According to the WHO report of 2021, approximately 10 million new cases were reported in 2020, of which 1 million occurred in the pediatric population. However, epidemiological data available on tuberculosis (TB) in pediatric age are extremely limited due to diagnostic challenges in this patient category. Furthermore, children are almost never included in national surveillance systems due to the lack of connections between individual pediatricians, pediatric hospitals, and national surveillance programs. It is therefore reasonable to assume that the disease may be significantly underestimated both in Italy and worldwide.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In recent decades, Tuberculosis (TB) has been considered, in industrialized countries, as predominantly an infectious disease of the elderly. However, since the 2000s, TB has re-emerged not only in the elderly but also in the young and especially in pediatric populations. Among the factors influencing the increase in the incidence of this pathology are certainly to be considered the rise in immigration from countries with high endemicity, where TB still represents a significant cause of morbidity and mortality, the spread of immunodeficiency caused by HIV infection, the use of immunosuppressive drugs, and the emergence of strains of M. tuberculosis resistant to traditional antibiotic therapy.

According to the WHO report of 2021, approximately 10 million new cases were reported in 2020, of which 1 million occurred in the pediatric population. However, epidemiological data available on TB in pediatric age are extremely limited due to diagnostic difficulties in this patient category. In children, in fact, bacteriological examination is negative in 95% of cases, and the diagnosis is made through a combination of clinical criteria and tests that are poorly specific for tuberculous infection and especially not universally accepted. In addition to diagnostic controversies, children are almost never included in national surveillance systems due to the lack of connections between individual pediatricians, pediatric hospitals, and national surveillance programs. It is therefore reasonable to assume that this condition may be significantly underestimated both in Italy and worldwide.

Another important aspect to consider is that tuberculous disease, whether active or latent, in a child should be considered a sentinel event that indicates recent transmission of M. tuberculosis within the community. Especially in the pediatric population, in addition to the mandatory reporting of confirmed cases of TB disease, it is important to identify cases of latent TB through historical and diagnostic criteria. Children indeed have a greater likelihood that the disease will progress to the active form compared to adults and that the progression will be towards a more severe form. Children with latent tuberculous infection also become a reservoir for the transmission of the infection, fueling future epidemics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pediatric patients (0-18 years old) at the time of the initial observation
* Patients affected by active and latent TB, as defined by the criteria of the World Health Organization
* Patients exposed to TB who are found to be non-infected at the end of the window period
* Informed consent signed by parents/legal guardian or by the patient who has reached the legal age of consent, assent of the minor

Exclusion Criteria

* None
Minimum Eligible Age

1 Week

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Meyer Children's Hospital IRCCS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Luisa Galli

Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Meyer Children's Hospital IRCCS

Florence, Firenze, Italy

Site Status RECRUITING

Ospedale Pediatrico Giovanni XXIII

Bari, , Italy

Site Status RECRUITING

Ospedale di Belluno

Belluno, , Italy

Site Status RECRUITING

Università di Bologna

Bologna, , Italy

Site Status RECRUITING

IRCCS Istituto Giannina Gaslini

Genova, , Italy

Site Status RECRUITING

Fondazione IRCCS Ca' Granda, Ospedale Maggiore, Policlinico

Milan, , Italy

Site Status RECRUITING

Ospedale Luigi Sacco

Milan, , Italy

Site Status RECRUITING

Policlinico di Modena

Modena, , Italy

Site Status RECRUITING

Università Federico II

Napoli, , Italy

Site Status RECRUITING

Ospedale dei Bambini "G.Di Cristina"

Palermo, , Italy

Site Status RECRUITING

Ospedale di Parma

Parma, , Italy

Site Status RECRUITING

IRCCS Policlinico San Matteo

Pavia, , Italy

Site Status RECRUITING

Azienda Ospedaliero Universitaria Pisana

Pisa, , Italy

Site Status RECRUITING

Azienda USL Toscana Centro

Prato, , Italy

Site Status RECRUITING

IRCCS Ospedale Pediatrico Bambin Gesù

Roma, , Italy

Site Status RECRUITING

Policlinico Universitario Agostino Gemelli IRCCS

Roma, , Italy

Site Status RECRUITING

Ospedale Regina Margherita

Torino, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Luisa Galli, MD

Role: CONTACT

+390555662439

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Luisa Galli

Role: primary

Desiree Caselli

Role: primary

Giangiacomo Nicolini

Role: primary

Marcello Lanari

Role: primary

Elio Castagnola

Role: primary

Samantha Bosis, MD

Role: primary

Vania Giacomet

Role: primary

Barbara Maria Bergamini

Role: primary

Andrea Lo Vecchio

Role: primary

Claudia Colomba, MD

Role: primary

Susanna Maria Roberta Esposito

Role: primary

Gian Luigi Marseglia

Role: primary

Diego Peroni

Role: primary

Per Luigi Vasarri

Role: primary

Laura Lancella

Role: primary

Danilo Buonsenso, MD

Role: primary

Silvia Garazzino

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PED-TB22

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Infant TB Infection Prevention Study
NCT02613169 COMPLETED PHASE2